| Old Articles: <Older 4891-4900 Newer> |
|---|
 |
The Motley Fool
June 6, 2008
Brian Lawler |
Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them.   |
The Motley Fool
June 5, 2008
Brian Lawler |
Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth. |
The Motley Fool
June 5, 2008
Brian Orelli |
Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry. |
The Motley Fool
June 5, 2008
Brian Lawler |
Cancer Concerns Fuel FDA Inquiry The agency examines a class of blockbuster drugs for a link to cancer in young patients. |
The Motley Fool
June 4, 2008
Brian Lawler |
Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares. |
The Motley Fool
June 4, 2008
Brian Orelli |
Expanding Possibilities Fail to Expand Rigel's Stock Price Rigel gets positive data on a second indication for its lead drug, R788. |
The Motley Fool
June 3, 2008
Brian Orelli |
Taking a Walk With a 10-Bagger Acorda Therapeutics gets it done with phase 3 trial data on a new MS drug. |
The Motley Fool
June 2, 2008
Brian Lawler |
Ligand's Hail-Mary Touchdown The drugmaker receives an unexpected advisory-panel surprise regarding its lead drug, Promacta. |
The Motley Fool
June 2, 2008
Brian Orelli |
The Anticoagulation Competition Bloodbath Bayer and Johnson & Johnson give Sanofi's Lovenox another beating. |
The Motley Fool
June 2, 2008
Brian Orelli |
Valuing One-Drug Wonders With only one drug on the market, these pharmas lack positive earnings. |
| <Older 4891-4900 Newer> Return to current articles. |
